Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
2018 · Gastroenterology · 487 citations
https://doi.org/10.1053/j.gastro.2018.03.029
M
Mark H. O’Hara
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
222
Papers
5.8K
Citations
33
h-index
54
i10-index
Mark H. O’Hara is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Pancreatic and Hepatic Oncology Research & Cancer Genomics and Diagnostics. The author has an h-index of 33, co-authored 189 publications.
ORCID: 0000-0003-2751-6122Papers by this author
worksPhase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
2019 · Molecular Therapy · 357 citations
https://doi.org/10.1016/j.ymthe.2019.07.015
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
2022 · Nature Medicine · 325 citations
https://doi.org/10.1038/s41591-022-01829-9
Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer
2019 · JAMA Oncology · 277 citations
https://doi.org/10.1001/jamaoncol.2019.0684
Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting
2021 · Nature Communications · 108 citations
https://doi.org/10.1038/s41467-021-24562-2
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic Cancer
2020 · Molecular Therapy · 55 citations
https://doi.org/10.1016/j.ymthe.2020.07.017
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat